Research Article
Ki-67 Index Provides Long-Term Survival Information for Early-Stage HER2-Low-Positive Breast Cancer: A Single-Institute Retrospective Analysis
Table 1
Baseline characteristics of HER2-nonamplified patients.
| | | HER2-0 patients (n = 536) | HER2-low-positive (n = 1694) | p value |
| | Age, years | | | | | Median, (range) | 53, (22–88) | 55, (24–92) | P = 0.17 | | <30 year | 5 (0.1%) | 10 (0.6%) | P = 0.06 | | 30-<40 years | 60 (11.2%) | 137 (8.0%) | | | 40-<50 years | 133 (24.8%) | 425 (25.1%) | | | 50-<60 years | 149 (27.8%) | 495 (29.2%) | | | 60–70 years | 113 (21.1%) | 413 (24.4%) | | | ≥70 years | 76 (14.2%) | 214 (12.6%) | |
| | Hormone receptors status | | | p < 0.0001 | | Negative | 166 (31.0%) | 299 (17.7%) | | | Positive | 370 (69.0%) | 1395 (82.3%) | |
| | Grading | | | P = 0.10 | | Grade I | 40 (7.5%) | 81 | | | Grade II | 177 (33.0%) | 734 | | | Grade III | 145 (27.1%) | 432 | | | Unknown | 174 (32.4%) | 447 | |
| | pT stage | | | P = 0.065 | | pT1mi | 1 (0.2%) | 9 (0.5%) | | | pT1a | 28 (5.2%) | 57 (3.4%) | | | pT1b | 86 (16.0%) | 278 (16.4%) | | | pT1c | 207 (38.6%) | 733 (43.2%) | | | pT2 | 179 (33.4%) | 518 (30.6%) | | | pT3 | 9 (1.7%) | 35 (2.1%) | | | pTx | 26 (4.3%) | 64 (3.8%) | |
| | pN stage | | | P = 0.05 | | Negative LN | 407 (75.9%) | 1213 (71.6%) | | | One positive LN | 66 (12.3%) | 274 (16.2%) | | | Two positive LN | 40 (7.5%) | 131 (7.7%) | | | Three positive LN | 23 (4.3%) | 76 (4.5%) | |
| | Histologic types | | | P = 0.073 | | No special type | 377 (70.3%) | 1306 (77.1%) | | | Invasive lobular | 12 (2.2%) | 41 (2.4%) | | | Mucinous | 29 (5.4%) | 60 (3.5%) | | | Other | 118 (22.0%) | 287 (16.9%) | |
| | Ki-67 | | | P = 0.11 | | ≤14.0% | 257 (47.9%) | 778 (45.9%) | | | >14% | 279 (52.1%) | 916 (54.1%) | |
| | Types of surgery | | | P = 0.026 | | Mastectomy | 344 (64.2%) | 1035 (61.1%) | | | BCS | 192 (35.8%) | 659 (38.9%) | |
| | Adjuvant chemotherapy | | | P = 0.31 | | Yes | 290 (54.1%) | 872 (51.5%) | | | No | 246 (45.9%) | 822 (48.5%) | |
| | Adjuvant hormonal therapy | | | P < 0.0001 | | Yes | 342 (63.8%) | 1340 (79.1%) | | | No | 194 (36.2%) | 354 (20.9%) | |
| | Adjuvant radiotherapy | | | P = 0.12 | | Yes | 287 (53.5%) | 840 (49.6%) | | | No | 249 (46.5%) | 854 (50.4%) | |
| | Stage | | | P = 0.63 | | IA | 257 (47.9%) | 828 (48.9%) | | | IB | 2 (0.4%) | 7 (0.4%) | | | IIA | 185 (34.5%) | 551 (32.5%) | | | IIB | 65 (12.1%) | 234 (13.8%) | | | IIIA | 1 (0.2%) | 8 (0.5%) | | | Unknown | 26 (4.9%) | 64 (3.8%) | |
|
|
Abbreviations: LN, lymph node.
|
